Liminatus Pharma, Inc. (LIMN) News
Track canonical SquawkNews coverage tagged to LIMN, Liminatus Pharma, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 7 indexed stories across 4 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Liminatus Pharma transfers to Nasdaq Capital Market, gets bid-price extension
Liminatus Pharma (LIMN) announces its transfer to the Nasdaq Capital Market and an extension aimed at regaining compliance with the Nasdaq minimum bid price requirement.
REGULATION | Aug 13, 2026, 11:15 AM UTC
H
Dow Gains Over 250 Points; US Jobs Rise By 57,000 In June
U.S. stocks traded higher this morning, with the Dow Jones index gaining over 250 points on Thursday. Following the market opening Thursday, the Dow traded up 0.47% to 52,553.59 while the NASDAQ rose 0.32% to 26,124.28.
MACRO | Jul 02, 2026, 01:50 PM UTC
H
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Liminatus Pharma (NASDAQ: LIMN ) stock increased by 40.9% to $0.16 during Thursday's pre-market session. The market value of their outstanding shares is at $5.8 million. Stablecoin Development (AMEX: SDEV ) stock
EARNINGS | Jul 02, 2026, 12:05 PM UTC
H
Why SurgePays Shares Are Trading Higher By 59%; Here Are 20 Stocks Moving Premarket
Shares of Surgepays Inc (NASDAQ: SURG ) rose sharply in pre-market trading after the Tennessee-based wireless and fintech company amended its agreement with a Tier 1 wholesale wireless network provider. The deal restruct
RATES | Jul 02, 2026, 09:32 AM UTC
H
Liminatus Pharma (LIMN) Stock Is Trending Overnight — Here’s Why it Spiked Over 30% in After-Hours Session
Liminatus Pharma, Inc. (NASDAQ: LIMN ) shares are trending on Wednesday night. Shares of the California-based immuno-oncology biotechnology company jumped 30.49% to $0.15 in after-hours trading after Liminatus amended an
MNA | Jul 02, 2026, 04:05 AM UTC
H
Liminatus Pharma shares are trading lower. The company announced it amended its proposed $320 merger deal with InnocsAI.
Liminatus Pharma shares are trading lower. The company announced it amended its proposed $320 merger deal with InnocsAI.
MNA | Jul 01, 2026, 01:21 PM UTC
H
Liminatus Pharma Amends Proposed $320M Merger Deal With InnocsAI As Closing Now Anticipated Before Shareholder Approval On July 2
Liminatus Pharma, Inc. (Nasdaq: LIMN ) ("Liminatus" or the "Company"), a biotechnology company developing innovative cancer therapies, today announced that it has amended and restated the previously announced definitive
MNA | Jun 30, 2026, 08:32 PM UTC